HALIFAX, Feb. 2, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a
developer and marketer of rapid diagnostic technology and solutions,
today announced that the Company's Board of Directors was elected at
MedMira's 2012 Annual General and Special Meeting of Shareholders,
which was held on January 30th, 2012. Mr. Hermes Chan, Dr. Shou-Ching
Tang, Mr. Romano Robusto and Mr. Markus Meile were re-elected as
directors of the Company.
"MedMira's Board of Directors provides strategic insight and direction
on business execution to the Company's management team as it moves
forward on key strategies for 2012," said Hermes Chan, CEO and
Director, MedMira. "The Company is committed to positioning itself for
growth by building on success, including China market penetration and
the US Army contract. MedMira will transform structurally into
distinct and focused business units, implement automation in its
manufacturing processes, and restore its financial condition. Most
importantly, we will continue to innovate, bringing new products to
market and building our brand in high growth niche markets."
Shareholders approved all other matters considered at the meeting
including the appointment of Deloitte & Touche LLP as the Company's
auditors and ratification of the stock option plan.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. The Company's tests provide hospitals,
labs, clinics and individuals with reliable, rapid diagnosis of
infectious diseases. MedMira diagnostics are sold under the Reveal®,
MiraWell®, Multiplo™, and Miriad brands in global markets. MedMira's
rapid HIV test is the only rapid HIV test in the world to achieve
regulatory approvals in Canada, the United States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada. For more
information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, including
statements regarding development of sales opportunities, which involve
risk and uncertainties and reflect the company's current expectation
regarding future events. Actual events could materially differ from
those projected herein and depend on a number of factors including, but
not limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
SOURCE MEDMIRA INC.
For further information:
MedMira Contact: Andrea Young